iBio (IBIO) Total Current Assets : $8.29 Mil (As of Dec. 2024)

View and export this data going back to 2008. Start your Free Trial

What is iBio Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. iBio's total current assets for the quarter that ended in Dec. 2024 was $8.29 Mil.

iBio Total Current Assets Historical Data

The historical data trend for iBio's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iBio Total Current Assets Chart

iBio Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Current Assets

Get a 7-Day Free Trial

61.75

104.60

45.07

26.26

15.67

iBio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Current Assets	Get a 7-Day Free Trial															19.70	36.14	15.67	11.71	8.29

iBio Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

iBio's Total Current Assets for the fiscal year that ended in Jun. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	14.21	+	0.713	+	0	+	0.749
	=	15.67

iBio's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	7.015	+	0.013	+	0	+	1.257
	=	8.29

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

iBio (NAS:IBIO) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

iBio's Liquidation Value for the quarter that ended in Dec. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	7.015	-	7.802	+	0.75 * 0	+	0.5 * 0
=	-0.79

iBio Total Current Assets Related Terms

Thank you for viewing the detailed overview of iBio's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

iBio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iBio Inc (NAS:IBIO) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

11750 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.ibioinc.com

iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.

Executives

Gary Sender	director	C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVE, NEW YORK NY 10020
Felipe Duran	officer: Interim CFO	8800 HSC PARKWAY, BRYAN TX 77807
William D Clark	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Martin Brenner	officer: Chief Scientific Officer	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Evert B. Schimmelpennink	director	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Isett Thomas Francis 3rd	director, officer: CEO and Executive Chairman	C/O IBIO INC. 600 MADISON AVENUE, SUITE 1601, NEW YORK NY 10022
Robert Matthew Lutz	officer: See Remarks	900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Randy Joe Maddux	officer: Chief Operating Officer	2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Alexandra Kropotova	director	RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807
Linda Washington Armstrong	director	8800 HSC PARKWAY, BRYAN TX 77807
John Delta	officer: Principal Accounting Officer	8800 HSC PARKWAY, BRYAN TX 77807
Eastern Capital Ltd	10 percent owner	10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Robert L Erwin	officer: President	C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
James P. Mullaney	officer: Chief Financial Officer	C/O IBIO, INC., 600 MADISON AVE., SUITE 1601, NEW YORK NY 10022
Carl Desantis	10 percent owner	C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431